The global left atrial appendage closure (LAAC) devices market is projected to register a robust growth from 2025 to 2033. Market growth is underpinned by a rapidly expanding AFib patient population, ...
New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...
Please provide your email address to receive an email when new articles are posted on . OPTION is a head-to-head trial of left atrial appendage closure with Watchman FLX vs. anticoagulation after ...
Results of the Embolic Protection in Patients with Atrial Fibrillation (PROTECT-AF) showed that in AF patients who were candidates for warfarin therapy, device closure of the LAA using the Watchman ...
Boston Scientific and Abbott this week both put forward separate studies supporting their respective implants for sealing off the heart’s left atrial appendage—the pocket within the cardiac muscle ...
CHICAGO -- For patients at high risk of stroke who underwent catheter-based atrial fibrillation ablation, left atrial appendage closure led to less bleeding compared with oral anticoagulation, the ...
TCT 489: The Comparison of Tissue Characteristics of Restenosis After Coronary Interventions: Insights From a Histological Analysis After Directional Coronary Atherectomy Receive the the latest news, ...
A team of specialists at Jacksonville, Fla.-based Baptist Health has become the first in the U.S.’ Southeast region to implant the Amplatzer Amulet Left Atrial Appendage Occluder. The device is meant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback